~~CLAIMS~~

~~1. A method of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.~~

~~2. The method of claim 1, wherein the Epidermolysis Bullosa is Epidermolysis Bullosa Simplex, Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, or Kindler's Syndrome.~~

~~3. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration from about one week to about twelve weeks.~~

~~4. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 14 times per week for the treatment duration.~~

~~5. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 7 times per week, for the treatment duration.~~

~~6. The method of any one of claims 1-5, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a day, for the treatment duration.~~

~~7. The method of any one of claims 1-5, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once a day, for the treatment duration.~~

~~8. The method of any one of claims 1-5, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once every two days, for the treatment duration.~~

~~9. The method of any one of claims 1-5, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a week, for the treatment duration.~~

10. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about two weeks.

11. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about three weeks.

12. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about four weeks.

13. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about five weeks.

14. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about six weeks.

15. The method of any one of claims 1-9, wherein administration of the pharmaceutical composition comprising CoQ10 to an affected area containing at least one blister and/or wound for a treatment duration of about four weeks results in at least 70% reduction in the size of the affected area containing at least one blister and/or wound.

16. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).

17. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).

18. The method of any one of the preceding claims, wherein administration of the pharmaceutical composition comprising CoQ10 to the subject provides one or more beneficial effects to the subject.

19. The method of claim 18, wherein the one or more beneficial effect is selected from the group consisting of:

a. Reduction in pain associated with the EB;

b. Reduction in inflammation associated with the EB;

c. Reduction in the size of blisters and/or wounds associated with the EB;

d. Reduction in the number of blisters and/or wounds associated with the EB;

e. Increase in the rate of healing of one or more blisters and/or wounds associated with the EB;

f. Increase in the structural integrity of the skin of the subject suffering from EB;

g. Reduction in the number of skin infections associated with EB;

h. Increase in wound closure of wounds associated with EB;

i. Increase in re-epithelization of wounds associated with EB;

j. Increase in granulation of wounds associated with EB;

k. Reduction in an epidermal gap distance of a blister and/or wound associated with EB;

l. Reduction in time for blister and/or wound healing associated with EB;

m. Reduction in the amount of concomitant medications administered to the subject in order to treat the subject's EB;

n. Reduction in scarring associated with EB;

o. Increase in keratinocyte production in the skin of the subject; and

p. Increase in fibroblast production in the skin of the subject.

20. A method of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of CoQ10 to the subject, wherein treatment of the subject results in the reduction of size of one or more blisters and/or wounds by at least about 70%

~~after administration of an effective amount of CoQ10 for a treatment duration of about four weeks.~~

~~21. The method of claim 20, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).~~

~~22. The method of claim 20 or 21, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).~~

~~23. The method of any one of claims 20-22, wherein administration of the CoQ10 to the subject provides a beneficial effect to the subject.~~

~~24. The method of claim 23, wherein the beneficial effect is one or more of the group selected from:~~

~~a. Reduction in pain associated with the EB;~~

~~b. Reduction in inflammation associated with the EB;~~

~~c. Reduction in the size of blisters and/or wounds associated with the EB;~~

~~d. Reduction in the number of blisters and/or wounds associated with the EB;~~

~~e. Increase in the rate of healing of one or more blisters and/or wounds associated with the EB;~~

~~f. Increase in the structural integrity of the skin of the subject suffering from EB;~~

~~g. Reduction in the number of skin infections associated with EB;~~

~~h. Increase in wound closure of wounds associated with EB;~~

~~i. Increase in re-epithelization of wounds associated with EB;~~

~~j. Increase in granulation of wounds associated with EB;~~

~~k. Reduction in an epidermal gap distance of a blister and/or wound associated with EB;~~

~~l. Reduction in time for blister and/or wound healing associated with EB;~~

m. Reduction in the amount of concomitant medications administered to the subject in order to treat the subject's EB;

n. Reduction in scarring associated with EB;

o. Increase in keratinocyte production in the skin of the subject; and

p. Increase in fibroblast production in the skin of the subject.

25. A method of treating a wound associated with Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of CoQ10 to the subject.

26. The method of claim 25, wherein the Epidermolysis Bullosa is Epidermolysis Bullosa Simplex, Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, or Kindler's Syndrome.

27. The method of any one of claims 25 or 26, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration from about one week to about twelve weeks.

28. The method of any one of claims 24-27, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 14 times per week for the treatment duration.

29. The method of any one of claims 24-28, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 7 times per week, for the treatment duration.

30. The method of any one of claims 24-27, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a day, for the treatment duration.

31. The method of any one of claims 24-28, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once a day, for the treatment duration.

~~32. The method of any one of claims 24-28, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once every two days, for the treatment duration.~~

~~33. The method of any one of claims 24-28, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a week, for the treatment duration.~~

~~34. The method of any one of claims 24-33, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about two weeks.~~

~~35. The method of any one of claims 24-34, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about three weeks.~~

~~36. The method of any one of claims 24-35, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about four weeks.~~

~~37. The method of any one of claims 24-36, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about five weeks.~~

~~38. The method of any one of claims 24-37, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about six weeks.~~

~~39. The method of any one of claims 24-36, wherein administration of the pharmaceutical composition comprising CoQ10 to an affected area containing at least one blister and/or wound for a treatment duration of about four weeks results in at least 70% reduction in the size of the affected area containing at least one blister and/or wound.~~

~~40. The method of any one of claims 24-39, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).~~

~~41. The method of claim 40, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).~~

~~42. The method of any one of claims 24-41, wherein administration of the pharmaceutical composition comprising CoQ10 to the subject provides one or more beneficial effects to the subject.~~

~~43. The method of claim 42, wherein the one or more beneficial effect is selected from the group consisting of:~~

~~a. Reduction in pain associated with the EB;~~

~~b. Reduction in inflammation associated with the EB;~~

~~c. Reduction in the size of blisters and/or wounds associated with the EB;~~

~~d. Reduction in the number of blisters and/or wounds associated with the EB;~~

~~e. Increase in the rate of healing of one or more blisters and/or wounds associated with the EB;~~

~~f. Increase in the structural integrity of the skin of the subject suffering from EB;~~

~~g. Reduction in the number of skin infections associated with EB;~~

~~h. Increase in wound closure of wounds associated with EB;~~

~~i. Increase in re-epithelization of wounds associated with EB;~~

~~j. Increase in granulation of wounds associated with EB;~~

~~k. Reduction in an epidermal gap distance of a blister and/or wound associated with EB;~~

~~l. Reduction in time for blister and/or wound healing associated with EB;~~

~~m. Reduction in the amount of concomitant medications administered to the subject in order to treat the subject's EB;~~

~~n. Reduction in scarring associated with EB;~~

~~o. Increase in keratinocyte production in the skin of the subject; and~~

~~p. Increase in fibroblast production in the skin of the subject.~~

~~44. A method of improving the structural integrity of the skin of a subject suffering from Epidermolysis Bullosa, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of CoQ10 to the skin of the subject.~~

~~45. The method of claim 44, wherein the poor structural integrity of the skin of the subject with EB is a result of a defect or deficiency in one or more structural and/or functional proteins.~~

~~46. The method of claim 45, where in the one or more structural and/or functional proteins is selected from a keratin, a collagen, a plectin, an annexin, a vimentin, a filamin, an integrin and a laminin.~~

~~47. The method of claim 46, wherein the keratin protein is selected from the group consisting of: keratin 5 (KRT5), keratin 13 (KRT13), keratin 14 (KRT14) and keratin 17 (KRT17).~~

~~48. The method of claim 46, wherein the collagen protein is selected from collagen XVII or type VII collagen.~~

~~49. The method of claim 46, wherein the laminin is laminin 332.~~

~~50. The method of claim 46, wherein the integrin is α6β4 integrin.~~

~~51. The method of claim 45 or 46, wherein the protein is selected from the group consisting of: transaldolase 1, NM23 protein, heat shock 27kDa protein 1, keratin 1, keratin 14, keratin 13, proteasome beta 7, proteasome activator subunit 3, and rho GDP dissociation inhibitor alpha.~~

~~52. The method of claim 45 or 46, wherein the protein is selected from the group consisting of: V-akt murine thymoma viral oncogene homolog 1 (AKT1), BCL2-associated athanogene 4 (BAG4), BCL2-associated X protein (BAX), BCL2-like 1 (BCL2L1), BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3), caspase recruitment domain family, member 6 (CARD6), caspase 6, apoptosis-related cysteine peptidase (CASP6), caspase 7, apoptosis-related cysteine peptidase (CASP7), growth arrest and DNA-damage-inducible, alpha (GADD45A), tumor protein p53 (TP53) and tumor protein p73 (TP73).~~

~~53. The method of any one of claims 45-52, wherein the defect or deficiency in the one or more structural and/or functional proteins is within the epidermis.~~

~~54. The method of any one of claims 45-52, wherein the defect or deficiency in the one or more structural and/or functional proteins is within lamina lucida.~~

55. The method of any one of claims 45-52, wherein the defect or deficiency in the one or more structural and/or functional proteins is in the sublamina densa zone.

56. The method of any one of claims 45-52, wherein the defect or deficiency in the one or more structural and/or functional proteins is within more than one of the epidermis, lamina lucida and sublamina densa zone.

57. The method of claim 53, wherein the EB is Epidermolysis Bullosa Simplex.

58. The method of claim 54, wherein the EB is Junctional Epidermolysis Bullosa.

59. The method of claim 55, wherein the EB is Dystrophic Epidermolysis Bullosa.

60. The method of claim 56, wherein the EB is Kindler's Syndrome.

61. The method of any one of claims 45-60, wherein the defect or deficiency in the one or more structural and/or functional proteins is one or more of a deficiency in protein activity, a deficiency in protein expression, and a mutation in the protein.

62. The method of claim 44, wherein the structural integrity of the skin is assessed by histological examination, transmission electron microscopy (TEM) or immunofluorescent staining of a skin biopsy from the subject.

63. The method of any one of claims 44-62, wherein an improvement in the structural integrity of the skin is determined by provision of one or more beneficial effect to the subject suffering from EB after treatment with an effective amount of CoQ10.

64. The method of claim 63, wherein the one or more beneficial effect is selected from the group consisting of:

a. Reduction in pain associated with the EB;

b. Reduction in inflammation associated with the EB;

c. Reduction in the size of blisters and/or wounds associated with the EB;

d. Reduction in the number of blisters and/or wounds associated with the EB;

e. Increase in the rate of healing of one or more blisters and/or wounds associated with the EB;

f. Increase in the structural integrity of the skin of the subject suffering from EB;

g. Reduction in the number of skin infections associated with EB;

h. Increase in wound closure of wounds associated with EB;

i. Increase in re-epithelization of wounds associated with EB;

j. Increase in granulation of wounds associated with EB;

k. Reduction in an epidermal gap distance of a blister and/or wound associated with EB;

l. Reduction in time for blister and/or wound healing associated with EB;

m. Reduction in the amount of concomitant medications administered to the subject in order to treat the subject's EB;

n. Reduction in scarring associated with EB;

o. Increase in keratinocyte production in the skin of the subject; and

p. Increase in fibroblast production in the skin of the subject.

65. The method of any one of claims 44-64, wherein an improvement in the structural integrity of the skin is determined by using a suction blister test on the skin of the subject suffering from EB after treatment with an effective amount of CoQ10.

66. The method of claim 65, wherein an increase in time to blister formation in the skin of the subject treated with CoQ10 is indicative of an improvement in the structural integrity of the skin of the subject.

67. The method of any one of claims 44-66, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).

68. The method of any one of claims 44-67, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).

69. A method of increasing the rate of healing of a skin blister and/or wound in a subject suffering from EB, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of Coenzyme Q10 (CoQ10) to the skin blister and/or wound.

70. The method of claim 69, wherein the rate of healing is determined by the rate of re-epithelialization of the skin blister and/or wound treated with the CoQ10 composition compared to the rate of re-epithelialization of an untreated blister and/or wound.

71. The method of claim 69, wherein the rate of healing is determined by a reduction in an epidermal gap distance of the skin blister and/or wound treated with the CoQ10 composition compared to the epidermal gap distance of an untreated skin blister and/or wound.

72. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered in the form of a CoQ10 cream at a dosage of CoQ10 between 0.01 mg/cm^2 and 5 mg/cm^2.

73. The method of any one of the preceding claims, wherein the pharmaceutical composition comprising CoQ10 is administered with a second composition comprising an additional agent.

74. The method of any one of the preceding claims, wherein the pharmaceutical composition further comprises an additional agent.

75. A method of treating or preventing squamous cell carcinoma in a subject suffering from Epidermolysis Bullosa, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of CoQ10 to the subject.

76. The method of claim 75, wherein the squamous cell carcinoma is cutaneous squamous cell carcinoma.

77. The method of claim 75 or 76, wherein the Epidermolysis Bullosa is Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, or Kindler’s Syndrome.

78. The method of any one of claims 75-77, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration from about one week to about twelve weeks.

79. The method of any one of claims75-78, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 14 times per week for the treatment duration.

80. The method of any one of claims 75-79, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 7 times per week, for the treatment duration.

81. The method of any one of claims 75-78, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a day, for the treatment duration.

82. The method of any one of claims 75-79, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once a day, for the treatment duration.

83. The method of any one of claims 75-79, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once every two days, for the treatment duration.

84. The method of any one of claims 75-79, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a week, for the treatment duration.

85. The method of any one of claims 75-84, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about two weeks.

86. The method of any one of claims 75-85, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about three weeks.

87. The method of any one of claims 75-86, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about four weeks.

88. The method of any one of claims 75-87, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about five weeks.

89. The method of any one of claims 75-88, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about six weeks.

90. The method of any one of claims 75-89, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).

91. The method of any one of claims 75-90, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).

92. The method of any one of claims 75-91, wherein the pharmaceutical composition comprising CoQ10 is administered in the form of a CoQ10 cream at a dosage of CoQ10 between 0.01 mg/cm^2 and 5 mg/cm^2.

93. The method of any one of claims 75-92, wherein the pharmaceutical composition is administered to intact skin and skin with one or more blisters and/or wounds.

94. The method of any one of claims 75-93, wherein the pharmaceutical composition is administered to intact skin.

95. The method of any one of claims 75-92, wherein the pharmaceutical composition is administered to skin with one or more blisters and/or wounds.

96. The method of any one of claims 75-95, wherein treatment of the subject results in the delayed onset of SCC, as compared to the average age of onset of SCC for the form of EB from which the subject suffers.

97. The method of any one of claims 75-96, wherein the pharmaceutical composition comprising CoQ10 is administered with a second composition comprising an additional agent.

98. The method of any one of claims 75-96, wherein the pharmaceutical composition further comprises an additional agent.

99. The method of claim 97 or 98, wherein the additional agent is a chemotherapeutic agent.

100. The method of claim 97, wherein the chemotherapeutic agent is cisplatin, doxorubicin, 5-fluorouracil, capecitabine, topotecan, or etoposide.

101. The method of claim 98, wherein the additional agent is 5-fluorouracil.

102. The method of claim 97 or 98, wherein the additional agent is diclofenac, imiquimod, or ingenol mebutate.

103. The method of claim 97 or 98, wherein the additional agent is a drug used in photodynamic therapy (PDT).

104. A topical pharmaceutical composition comprising a therapeutically effective amount of CoQ10 for use in the treatment of Epidermolysis Bullosa (EB) in a subject in need thereof.

105. The composition of claim 104, for use in the treatment of EB, wherein the treatment of EB comprises treatment of one or more blister and/or wound associated with EB.

106. The composition of claim 104 or 105, for use in the treatment of EB, wherein the treatment of EB comprises improving the structural integrity of the skin in a subject suffering from EB.

107. The composition of any one of claims 104-106, for use in the treatment of EB, wherein the EB is Epidermolysis Bullosa Simplex, Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, or Kindler's Syndrome.

108. The composition of any one of claims 104-107, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration from about one week to about twelve weeks.

109. The composition of any one of claims 104-108, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 14 times per week for the treatment duration.

110. The composition of any one of claims 104-109, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 7 times per week, for the treatment duration.

111. The composition of any one of claims 104-109, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a day, for the treatment duration.

~~112. The composition of any one of claims 104-110, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once a day, for the treatment duration.~~

~~113. The composition of any one of claims 104-110, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once every two days, for the treatment duration.~~

~~114. The composition of any one of claims 104-110, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a week, for the treatment duration.~~

~~115. The composition of any one of claims 104-114, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about two weeks.~~

~~116. The composition of any one of claims 104-115, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about three weeks.~~

~~117. The composition of any one of claims 104-116, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about four weeks.~~

~~118. The composition of any one of claims 104-117, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about five weeks.~~

~~119. The composition of any one of claims 104-118, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about six weeks.~~

~~120. The composition of any one of claims 104-117, wherein administration of the pharmaceutical composition comprising CoQ10 to an affected area containing at least one blister and/or wound for a treatment duration of about four weeks results in a at least 70% reduction in the size of the affected area containing at least one blister and/or wound.~~

~~121. The composition of any one of claims 104-120, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).~~

~~122. The composition of any one of claims 104-121, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).~~

~~123. The composition of any one of claims 104-122, wherein administration of the pharmaceutical composition comprising CoQ10 to the subject provides one or more beneficial effects to the subject.~~

~~124. The composition of claim 123, wherein the one or more beneficial effect is selected from the group consisting of:~~

~~a. Reduction in pain associated with the EB;~~

~~b. Reduction in inflammation associated with the EB;~~

~~c. Reduction in the size of blisters and/or wounds associated with the EB;~~

~~d. Reduction in the number of blisters and/or wounds associated with the EB;~~

~~e. Increase in the rate of healing of one or more blisters and/or wounds associated with the EB;~~

~~f. Increase in the structural integrity of the skin of the subject suffering from EB;~~

~~g. Reduction in the number of skin infections associated with EB;~~

~~h. Increase in wound closure of wounds associated with EB;~~

~~i. Increase in re-epithelization of wounds associated with EB;~~

~~j. Increase in granulation of wounds associated with EB;~~

~~k. Reduction in an epidermal gap distance of a blister and/or wound associated with EB;~~

~~l. Reduction in time for blister and/or wound healing associated with EB;~~

m. Reduction in the amount of concomitant medications administered to the subject in order to treat the subject's EB;

n. Reduction in scarring associated with EB;

o. Increase in keratinocyte production in the skin of the subject; and

p. Increase in fibroblast production in the skin of the subject.

125. A topical pharmaceutical composition comprising a therapeutically effective amount of CoQ10 for use in the treatment of squamous cell carcinoma (SCC) associated with Epidermolysis Bullosa (EB) in a subject in need thereof.

126. The pharmaceutical composition of claim 125, for use in treatment of SCC, wherein the SCC is cutaneous squamous cell carcinoma.

127. The method of claim 125 or 126, wherein the EB is Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, or Kindler's Syndrome.

128. The pharmaceutical composition of any one of claims 125-127, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration from about one week to about twelve weeks.

129. The pharmaceutical composition of any one of claims 125-128, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 14 times per week for the treatment duration.

130. The pharmaceutical composition of any one of claims 125-128, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject from 1 to about 7 times per week, for the treatment duration.

131. The pharmaceutical composition of any one of claims 125-129, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a day, for the treatment duration.

132. The pharmaceutical composition of any one of claims 125-130, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once a day, for the treatment duration.

~~133. The pharmaceutical composition of any one of claims 125-130, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about once every two days, for the treatment duration.~~

~~134. The pharmaceutical composition of any one of claims 125-130, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered to the subject about twice a week, for the treatment duration.~~

~~135. The pharmaceutical composition of any one of claims 125-134, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about two weeks.~~

~~136. The pharmaceutical composition of any one of claims 125-135, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about three weeks.~~

~~137. The pharmaceutical composition of any one of claims 125-136, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about four weeks.~~

~~138. The pharmaceutical composition of any one of claims 125-137, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about five weeks.~~

~~139. The pharmaceutical composition of any one of claims 125-138, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered for a treatment duration of at least about six weeks.~~

~~140. The pharmaceutical composition of any one of claims 125-139, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 contains from about 1% to about 5% CoQ10 (w/w).~~

~~141. The pharmaceutical composition of any one of claims 125-140, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 contains about 3% CoQ10 (w/w).~~

~~142. The pharmaceutical composition of any one of claims 125-141, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered in the form of a CoQ10 cream at a dosage of CoQ10 between 0.01 mg/cm^2 and 5 mg/cm^2.~~

~~143. The pharmaceutical composition of any one of claims 125-142, for use in the treatment of SCC, wherein the pharmaceutical composition is administered to intact skin and skin with one or more blisters and/or wounds.~~

~~144. The pharmaceutical composition of any one of claims 125-142, for use in the treatment of SCC, wherein the pharmaceutical composition is administered to intact skin.~~

~~145. The pharmaceutical composition of any one of claims 125-142, for use in the treatment of SCC, wherein the pharmaceutical composition is administered to skin with one or more blisters and/or wounds.~~

~~146. The pharmaceutical composition of any one of claims 125-145, for use in the treatment or prevention of SCC, wherein treatment or prevention of the subject results in the delayed onset of SCC, as compared to the average age of onset of SCC for the form of EB from which the subject suffers.~~

~~147. The pharmaceutical composition of any one of claims 125-146, for use in the treatment of SCC, wherein the pharmaceutical composition comprising CoQ10 is administered with a second composition comprising an additional agent.~~

~~148. The pharmaceutical composition of any one of claims 125-146, for use in the treatment of SCC, wherein the pharmaceutical composition further comprises an additional agent.~~

~~149. The method of claim 147 or 148, wherein the additional agent is a chemotherapeutic agent.~~

~~150. The method of claim 147, wherein the chemotherapeutic agent is cisplatin, doxorubicin, 5-fluorouracil, capecitabine, topotecan, or etoposide.~~

~~151. The method of claim 148, wherein the additional agent is 5-fluorouracil.~~

~~152. The method of claim 147 or 148, wherein the additional agent is diclofenac, imiquimod, or ingenol mebutate.~~

~~153. The method of claim 147 or 148, wherein the additional agent is a drug used in photodynamic therapy (PDT).~~

CLAIMS

1. An invention not claimed in any divisional application.